Breast Ductal Lavage and Fiberoptic Ductoscopy
Customize your policy alerts
Sign up for Aetna Policy 0517 alerts
Get alerted when Policy 0517 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's medical necessity and investigational positions for breast ductal lavage and fiberoptic ductoscopy, and the patient populations/procedures addressed (diagnosis of non-lactational sporadic nipple discharge, guidance of resection, and other uses). Applies to Aetna members and providers submitting claims to Aetna.
No material clinical or coverage changes in this revision.
Coverage Criteria and Rationale
Medically necessary
Aetna considers the following interventions medically necessary:
Experimental, investigational, or unproven
The following interventions are considered experimental, investigational, or unproven:
These uses are considered unproven because effectiveness has not been established.
Coverage rationale and use-cases
Evidence summary and context for clinical use
Supported by studies reporting high rates of inadequate samples, poor reproducibility, and limited sensitivity.
Examples in the literature: metabolomics and miRNA studies; FD sensitivity for malignant lesions up to 94.2% and increased when combined with cytology.
Companies report >90% of samples may have scant or no cells; Halo study showed only 19% with adequate cellularity.
FDS combined with methylene blue — reported clinical outcomes
Evidence-based observations from recent studies informing clinical use
Reported benefits observed in retrospective and prospective series; authors note sample limitations and recommend further study.
Ductal fluid biomarker analysis (miRNA)
Biomarker research using ductal fluid
Study by Do Canto et al. (2016) identified 17 differentially expressed miRNAs from DL fluid but authors emphasize need for larger validation studies.
Aetna excludes the use of ductal lavage, nipple aspiration tests, and fiberoptic ductoscopy when they are applied for population-based breast cancer screening, general risk assessment, or other indications that are not specifically listed as medically necessary in this policy. The policy lists these modalities (including named commercial systems such as ForeCYTE, MASCT, Pro-Duct Catheter, Halo, and Acueity) as experimental, investigational, or unproven for screening and risk-assessment uses because effectiveness has not been established.
When ductal lavage or nipple aspiration is proposed as an alternative to standard screening (mammography, clinical breast exam) or to assess average- or high-risk asymptomatic populations, providers should be aware these applications are not supported by Aetna and may be denied if billed for screening or risk-assessment indications.
NAF-based screening tests (for example, the ForeCYTE/MASCT/Halo systems) are not substitutes for established breast cancer screening modalities. The FDA has advised that nipple aspirate tests lack valid scientific data demonstrating they are effective screening tools, and Atossa/ForeCYTE received regulatory action including a warning letter and a voluntary recall.
Because many commercial NAF systems yield scant or no cellular material in a large proportion of samples, a negative NAF cytology result does not reliably exclude malignancy and positive or indeterminate results may be non-diagnostic; therefore these tests should not replace mammography or clinical evaluation.
Fiberoptic ductoscopy (FDS) can be limited or infeasible when there is no active nipple discharge because insertion of the ductoscope into a normal or non-discharging duct is difficult. Thin duct caliber, intraductal fibrous tissue or inflammatory secretions, and lesions located in terminal (distal) branches beyond the length/diameter of the ductoscope can prevent adequate visualization.
Studies using FDS with adjunctive techniques note these technical limitations and recommend complementary imaging (high-frequency ultrasound, MRI, or mammography) when necessary. Additionally, timing and choice of dyes (e.g., methylene blue absorption after 72 hours) and a recognized learning curve for the procedure introduce further practical constraints to routine use.
Ductal lavage and nipple aspiration tests have insufficient evidence to support their use as screening tests in high-risk or asymptomatic populations. Multiple federal and professional reviews (FDA, American Cancer Society, Institute of Medicine, BCBSA, CTAF) have concluded data are inadequate to recommend DL/NAF as independent screening modalities, and prospective trials assessing sensitivity, specificity, and impact on health outcomes are lacking.
Commercial proponents acknowledge a high rate of samples with very scant or no cells (>90% in company reports), which undermines clinical utility and contributes to the conclusion that these methods are not validated for routine screening or risk assessment.
Evidence from studies of women with known breast cancer indicates ductal lavage has low sensitivity for identifying existing malignancy. In a series where DL was performed on malignant breasts, only a minority of samples from malignant breasts contained abnormal cells, supporting the conclusion that DL is not an effective standalone test to detect existing breast cancer.
Because of this low sensitivity in malignant breasts and frequent inadequate cellular yield, DL should not be relied upon as a primary diagnostic test for detecting established breast cancer.
The extracted policy excerpts describe Aetna’s medical necessity and investigational positions and summarize supporting evidence, but they do not present an explicit, standalone paragraph framed as a formal not medically necessary determination within the provided excerpt. Instead, the policy lists specific medically necessary uses and enumerates interventions considered experimental, investigational, or unproven.
Operationally, this means that while several applications are identified as investigational/unproven (and thus excluded from coverage for those indications), the document excerpt does not include a separate, explicit blanket statement labeled “not medically necessary” in the text segments provided here.
CPT and ICD-10 Coding
| 88104 | Cytopathology, fluids, washings or brushings, except cervical or vaginal; smears with interpretation. |
| 88106 | Simple filter method with interpretation. |
| 88108 | Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique). |
| 88112 | Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal. |
| 88160 | Cytopathology, smears, any other source; screening and interpretation. |
| 88161 | Preparation, screening and interpretation. |
| 88162 | Extended study involving over 5 slides and/or multiple stains. |
| C50.011-C50.A2 | Malignant neoplasm of breast (range as listed). |
| D24.1-D24.9 | Benign neoplasm of breast (range as listed). |
| D05.00-D05.12 | Intraductal carcinoma in situ of breast. |
| N64.52 | Nipple discharge [non-lactational sporadic nipple discharge]. |
| N61.0-N61.1 | Inflammatory disorders of breast [non-lactational mastitis]. |
| N63.0-N63.42 | Unspecified lump in breast. |
| N64.3-N64.51, N64.53-N64.9 | Other disorders of breast. |
| T85.44xA-T85.44xS | Capsular contracture of breast implant. |
| Z12.39 | Encounter for other screening for malignant neoplasm of breast. |
| Z80.3 | Family history of malignant neoplasm of breast. |
| Z85.3 | Personal history of malignant neoplasm of breast. |
| No codes listed |
| No codes listed |
Provider Actions, Documentation, and Prior Authorization
Prior authorization may be required for referenced procedure/cytology codes
Obtain prior authorization for the procedure and cytology codes listed in this policy when required by the member's benefit plan; submit appropriate CPT/HCPCS codes (e.g., 19030, 77053, 77054, and cytopathology codes 88104–88162) for review per plan rules.
- Prior authorization expectation is based on member benefit rules and the specific indication.
No explicit PA codes specified in policy excerpts — verify plan rules
The policy excerpts do not specify formal prior authorization codes or an explicit universal PA requirement for ductal lavage or ductoscopy; check the member’s plan for any local PA rules or research/clinical-trial coverage exceptions.
No formal PA requirement stated for ductal lavage or ductoscopy
The document does not state a formal, policy-wide prior authorization mandate for ductal lavage or fiberoptic ductoscopy; follow the member’s benefit contract and local PA processes if applicable.
Unspecified provider action
(Placeholder — no specific action detailed in source).
Imaging sequence: HFUS first; FDS as complementary/localization tool
When evaluating pathologic nipple discharge, perform high-frequency ultrasound (HFUS) as the preferred first-line imaging; consider fiberoptic ductoscopy (FDS) when HFUS is non-diagnostic or to complement localization.
- HFUS is preferred first-line evaluation for patients with nipple discharge.
- Consider FDS if HFUS cannot identify the cause of pathologic nipple discharge.
No formal step therapy specified; use complementary imaging as clinically indicated
No step-therapy or mandatory sequencing is specified in the policy; use complementary imaging (US, mammography, MRI) as clinically appropriate before or alongside ductoscopy per cited study recommendations.
- Policy excerpts report studies recommending complementary imaging when necessary prior to or in conjunction with ductoscopy.
- No formal step-therapy requirements are listed in the document.
Document specific clinical indication and supporting diagnosis codes on claims
When submitting claims for the CPT/HCPCS codes referenced in this policy, document the specific clinical indication (for example, non-lactational sporadic nipple discharge) and include supporting ICD-10 diagnosis codes to justify medical necessity.
- Examples of covered diagnosis codes include malignant neoplasm of breast (C50.*), benign neoplasm (D24.*), intraductal carcinoma in situ (D05.*), and N64.52 (nipple discharge).
Record cannulation success, cell-yield adequacy, and cytologic findings
Document procedural details for lavage and cytology submissions: record successful cannulation, adequacy of cell yield (report if samples were scant or insufficient), and detailed cytologic findings because studies frequently report inadequate cellularity and variable reproducibility.
- Record whether cannulation of the target duct was successful.
- Indicate cell yield adequacy (e.g., sufficient epithelial cells or inadequate/scant cellularity).
- Include cytologic interpretation and any inter-observer review results if performed.
When using FDS with methylene blue, document timing, ductoscopic findings, and correlated imaging
If FDS is performed with immediate methylene blue injection, document the timing of methylene blue injection relative to surgery (studies report optimal surgery 12–24 hours after injection), ductoscopic findings (lesion morphology, location, hemorrhage, duct wall characteristics), and imaging results used for correlation.
- Note exact timing of methylene blue injection and interval to surgery (12–24 hours reported as optimal).
- Describe ductoscopic lesion features and duct wall appearance.
- Attach correlated imaging (US, mammography) results when available.
Risk of claim denial if codes are used for not-covered indications
Claims using the policy’s procedure or cytology codes for indications listed as not covered (for example, screening, family-history-only, unspecified breast lumps, or inflammatory breast conditions) may be denied; confirm the coded indication matches a covered use before submission.
- ICD-10 codes listed as not covered include screening (Z12.39), family history (Z80.3), personal history (Z85.3), unspecified lump (N63.*), and inflammatory disorders (N61.*) per the policy listings.
NAF samples often yield scant/no cells — document sample adequacy
Be aware that nipple aspiration and NAF collection tests commonly produce very scant or no cells — companies report over 90% of samples may be scant/acytologic — and such insufficient samples may be diagnostically unhelpful and affect coverage determination for clinical utility.
- Studies and company reports note >90% of NAF samples may contain very scant or no cells, limiting diagnostic value.
- Document and report sample inadequacy on the claim to support clinical context.
No additional explicit provider-authorization or denial triggers stated in excerpts
The cited excerpts do not identify specific provider authorization triggers or unique denial criteria beyond the documentation, coverage, and indication-based denial risks noted above; follow the member’s benefit rules and policy coding guidance.
Background and Procedure Overview
Ductal lavage (DL) is a catheter-based procedure to obtain epithelial cells from individual breast ducts for cytologic examination. The technique involves cannulation of a ductal orifice at the nipple, infusion of saline to wash the ductal lumen, and collection of the lavage fluid for cytology.
DL and related approaches (nipple aspiration, Halo-type collection systems) aim to sample ductal epithelial cells without excisional biopsy; however, yield is frequently low and procedures may be performed in operating-room or clinic settings depending on clinical context and the need for concurrent surgery or tissue diagnosis.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.